Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Avadel Pharma (AVDL) Tops Q4 EPS by 30c; Reaffirms
March 7, 2017 6:34 AM ESTAvadel Pharma (NASDAQ: AVDL) reported Q4 EPS of $0.00, $0.30 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $43.1 million versus the consensus estimate of $34.95 million.
Total revenues for fourth quarter and full year 2016 were $43.1 million and $150.2 million, compared to $44.6... More